Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

David Jack

Obesity Medicine Draper, UT Medical Doctor

NPI 1255434296 CMS profile 399037

74 E Kimballs Ln Ste 260, Draper, UT 84020

Open in the dashboard

General payments

$6,086

220 records reported · program years 2019–2022

Research payments

$15,319

Paid to them · 14 records reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,097,436 paid to institutions, not to them · program years 2019–2025

Through program year 2022, David Jack of Draper, UT is reported in the CMS Open Payments database as having received $6,086 across 220 general payments and $15,319 in research payments paid to them. Separately, studies naming them as principal investigator received $1,097,436 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Obesity Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $2,783 25
2021 General $1,252 73
2021 Research $13,031 2
2020 General $948 43
2020 Research $1,274 1
2019 General $1,102 79
2019 Research $1,013 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Jack
  • Obesity Medicine median
  • Middle half of Obesity Medicine
  • National median

In program year 2025, general payments to David Jack were reported at $0. Among 57 Obesity Medicine profiles paid that year, the median was $178 and the middle half received between $105 and $508.

Show as a table
Year David Jack Obesity Medicine median Middle half National median
2019 $1,102 $96 $24–$339 $163
2020 $948 $53 $25–$124 $114
2021 $1,252 $113 $40–$251 $132
2022 $2,783 $160 $53–$375 $149
2023 $0 $125 $34–$398 $160
2024 $0 $136 $81–$475 $164
2025 $0 $178 $105–$508 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Eli Lilly and Company $2,571 14 payments
  2. Amgen Inc. $360 23 payments
  3. Novo Nordisk Inc $305 24 payments
  4. Astellas Pharma US Inc $247 11 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $208 12 payments
  6. Lilly USA, LLC $186 16 payments
  7. Boston Scientific Corporation $171 9 payments
  8. Amarin Pharma Inc. $165 9 payments
  9. AbbVie, Inc. $156 7 payments
  10. Horizon Therapeutics plc $151 3 payments
  11. Other $1,566 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,509 205 payments
  2. Travel and Lodging $2,424 12 payments
  3. Education $92 2 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $60 1 payment
Products named General payments · program years 2019–2022
  1. Repatha $251 16 payments
  2. AIMOVIG $250 16 payments
  3. Otezla $175 11 payments
  4. MYRBETRIQ $167 10 payments
  5. KRYSTEXXA $151 3 payments
  6. Ozempic $149 18 payments
  7. Vascepa $147 8 payments
  8. EMGALITY $136 11 payments
  9. VRAYLAR $133 6 payments
  10. FARXIGA $125 9 payments
  11. Other $2,702 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2022
  1. Eli Lilly and Company $14,305 3 payments
  2. AbbVie, Inc. $1,013 11 payments

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obesity Medicine in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record